Patent Trial and Appeal Board agreed with Axonics on its challenges to some claims in one Medtronic patent, while upholding one claim in that patent and all claims in two other patents.
- The PTAB agreed with Axonics on four of the five claims it contested in patent number 7,774,069, the companies said in separate statements; Medtronic said that patent protects technology related to its recharge power control
- The PTAB upheld all the claims in two other patents, which Medtronic said protect technology related to its tined leads
- Axonics said those two patents expire soon, one on Nov. 9, 2021, and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.